Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Generation N5p+N1 Generation Definitions   Donating Investigator Kevin Campbell,   University of Iowa

Description
Homozyous mice are viable and fertile. They develop severe muscular dystrophy and cardiomyopathy with focal areas of necrosis. Severe dystrophic changes including necrosis, dystrophic calcification, fatty infiltration, central nucleation, fibrosis, atrophy and hypertrophy are detected in diaphragm and calf/thigh muscle. Some of these changes occur in 4-week-old animals and accumulate with age. At 20 weeks of age, several regions of focal myocardial necrosis have been observed; small areas of necrotic myocardiocytes may be observed as early as 9 weeks of age. At 30 weeks of age, large areas of fibrosis are detected. Sarcoglycan-sarcospan and dystroglycan complexes are disrupted in skeletal, cardiac, and smooth muscle membranes. Loss of the sarcoglycan-sarcospan complex in vascular smooth muscle results in vascular irregularities in heart, diaphragm, and kidneys. Vascular constrictions in skeletal muscle, cardiac muscle and kidneys is observed. Epsilon-sarcoglycan (SGCE) is also reduced in membrane preparations of striated and smooth muscle. Northern blot analysis of skeletal muscle with an exon 6 probe reveals no transcript in the skeletal muscle of homozygous mice. This mutant mouse strain represents a model that may be useful in studies of muscular dystrophy, cardiomyopathy, and smooth muscle dysfunction.

Development
A targeting vector containing a neomycin resistance gene was used to replace exons 3-6 of the gene. The construct was electroporated into (129X1/SvJ x 129S1/Sv)F1-Kitl⁺-derived R1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts. Chimeric animals were backcrossed to C57BL/6 five times by the donating laboratory.

Control Information

	Control
	Wild-type from the colony
	000664 C57BL/6J
Considerations for Choosing Controls

Related Strains

Strains carrying   Sgcb^tm1Kcam allele

006831	129-Sgcbtm1Kcam/J
006832	B6.129-Sgcbtm1Kcam/1J

View Strains carrying   Sgcb^tm1Kcam     (2 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms

Muscular Dystrophy, Limb-Girdle, Type 2E; LGMD2E - Models with phenotypic similarity to human disease where etiologies involve orthologs.1

1 Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).

View Mammalian Phenotype Terms

Mammalian Phenotype Terms

      assigned by genotype

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

Sgcb^tm1Kcam/Sgcb^tm1Kcam

        involves: 129S1/Sv * 129X1/SvJ

• muscle phenotype
• abnormal muscle morphology (MGI Ref ID J:60154)
  • homozygotes exhibit loss of the sarcoglycan-sarcospan complex, the dystroglycan complex, and epsilon-sarcoglycan in skeletal, cardiac, and smooth muscles
• abnormal sarcolemma morphology (MGI Ref ID J:60154)
  • at 9 weeks, homozygotes display uptake of Evans blue dye in various skeletal muscles, indicating compromised sarcolemma integrity
• abnormal vascular smooth muscle morphology (MGI Ref ID J:60154)
  • homozygotes display loss of the sarcoglycan-sarcospan complex in vascular smooth muscles leading to vascular perturbation, exaggeration of the muscular dystrophy and initiation of cardiomyopathy
• myocardial necrosis (MGI Ref ID J:60154)
  • as early as 9 weeks, mutant hearts display small necrotic areas
  • at 20 weeks, focal necrotic areas resembling ischemic-like lesions are observed throughout the right and left ventricles; however, active myocardial necrosis is less prominent at 30 weeks
• cardiomyopathy (MGI Ref ID J:60154)
  • homozygotes develop significant cardiomyopathy with extensive regions of necrosis, similar to morphological changes noted in tissue infarcts
• muscle calcification (MGI Ref ID J:60154)
  • as early as 4 weeks, homozygotes exhibit progressive dystrophic calcification in the calf, thigh, and diaphragm muscles
• muscular atrophy (MGI Ref ID J:60154)
• dystrophic muscle (MGI Ref ID J:60154)
  • as early as 4 weeks, homozygotes exhibit progressive dystrophic changes in calf, thigh, and diaphragm muscles including pronounced areas of focal necrosis, dystrophic calcification, endomysial fibrosis, massive fatty infiltration, extensive central nucleation, fiber splitting and hypertrophy
  • consistent with severe muscular dystrophy, 13-16-wk-old homozygotes exhibit increased serum creatine kinase activity
• cardiovascular system phenotype
• abnormal blood vessel morphology (MGI Ref ID J:60154)
  • at 4 weeks, vessels of the mutant heart and diaphragm display a serrated contour, rather than the smoothly tapered vessel walls observed in wild-type mice
• abnormal vascular smooth muscle morphology (MGI Ref ID J:60154)
  • homozygotes display loss of the sarcoglycan-sarcospan complex in vascular smooth muscles leading to vascular perturbation, exaggeration of the muscular dystrophy and initiation of cardiomyopathy
• vascular stenosis (MGI Ref ID J:60154)
  • homozygotes display numerous areas of vascular constrictions often associated with pre- and poststenotic aneurysms in the vasculature of diaphragm, heart, and kidneys
  • vascular constrictions are detected prior to the onset of necrotic changes
• aneurysm (MGI Ref ID J:60154)
  • homozygotes exhibit multiple pre- and poststenotic aneurysms in vessels of the diaphragm, heart, and kidneys
• cardiac fibrosis (MGI Ref ID J:60154)
  • at 30 weeks, mutant hearts exhibit widespread areas of fibrosis
• cardiomyopathy (MGI Ref ID J:60154)
  • homozygotes develop significant cardiomyopathy with extensive regions of necrosis, similar to morphological changes noted in tissue infarcts
• myocardial necrosis (MGI Ref ID J:60154)
  • as early as 9 weeks, mutant hearts display small necrotic areas
  • at 20 weeks, focal necrotic areas resembling ischemic-like lesions are observed throughout the right and left ventricles; however, active myocardial necrosis is less prominent at 30 weeks

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Cardiovascular Research
Heart Abnormalities
      cardiomyopathy

Neurobiology Research
Neuromuscular Defects

Genes & Alleles

Gene & Allele Information

Allele Symbol		Sgcbtm1Kcam
Allele Name		targeted mutation 1, Kevin P Campbell
Allele Type		Targeted (knock-out)
Mutation Made By		Kevin Campbell,   University of Iowa
Strain of Origin		(129X1/SvJ x 129S1/Sv)F1-Kitl<+>
ES Cell Line Name		R1
ES Cell Line Strain		(129X1/SvJ x 129S1/Sv)F1-Kitl<+>
Gene Symbol and Name		Sgcb, sarcoglycan, beta (dystrophin-associated glycoprotein)
Chromosome		5
Gene Common Name(s)		A3b; AI747103; AI844814; LGMD2E; SGC; beta-SG; expressed sequence AI747103; expressed sequence AI844814;
Molecular Note		A loxP flanked neomycin cassette replaced a genomic fragment that contained exons 3-6. These exons encode part of the transmembrane domain and the extracellular portion of the protein. Northern blot analysis revealed that no transcript was detectable in skeletal muscle of homozygous mice and Western blot and immunohistochemical analysis demonstrated that the protein was absent in the sarcolemma of skeletal muscle derived from homozygous mice. [MGI Ref ID J:60154]

Genotyping

Genotyping Information

Genotyping Protocols

Generic Neo Melt Curve Analysis, Melt Curve Analysis
NEOTD (Generic Neo), Standard PCR
Sgcb^tm1Kcam, Standard PCR

Helpful Links

Genotyping resources and troubleshooting

References

References

Selected Reference(s)

Durbeej M; Cohn RD; Hrstka RF; Moore SA; Allamand V; Davidson BL; Williamson RA; Campbell KP. 2000. Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol Cell 5(1):141-51. [PubMed: 10678176]  [MGI Ref ID J:60154]

Additional References

Sgcb^tm1Kcam related

Cohn RD; Durbeej M; Moore SA; Coral-Vazquez R; Prouty S; Campbell KP. 2001. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest 107(2):R1-7. [PubMed: 11160141]  [MGI Ref ID J:66973]

Crosbie RH; Dovico SA; Flanagan JD; Chamberlain JS; Ownby CL; Campbell KP. 2002. Characterization of aquaporin-4 in muscle and muscular dystrophy. FASEB J 16(9):943-9. [PubMed: 12087055]  [MGI Ref ID J:120469]

Hanft LM; Bogan DJ; Mayer U; Kaufman SJ; Kornegay JN; Ervasti JM. 2007. Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy. Neuromuscul Disord 17(7):569-74. [PubMed: 17475492]  [MGI Ref ID J:124551]

Turk R; Sterrenburg E; van der Wees CG; de Meijer EJ; de Menezes RX; Groh S; Campbell KP; Noguchi S; van Ommen GJ; den Dunnen JT; 't Hoen PA. 2006. Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J 20(1):127-9. [PubMed: 16306063]  [MGI Ref ID J:104560]

Health & husbandry

Health & Colony Maintenance Information

Currently there no information available for this strain. This may be due to the supply level of this strain.

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Supply Details

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.

Supply Notes

Cryorecovery - Standard. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. The total number of animals provided, their gender and genotype will vary. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 13 and 16 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary. Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location). This strain is included in the Induced Mutant Resource Colony collection.

Control Information

	Control
	Wild-type from the colony
	000664 C57BL/6J
Considerations for Choosing Controls
USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
International - Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering and Purchasing Information

      Purchasing Information
      JAX^® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.